In vitro drug testing based on contractile activity of C2C12 cells in an epigenetic drug model

Kazushi Ikeda, Akira Ito, Ryusuke Imada, Masanori Sato, Yoshinori Kawabe, Masamichi Kamihira

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Skeletal muscle tissue engineering holds great promise for pharmacological studies. Herein, we demonstrated an in vitro drug testing system using tissue-engineered skeletal muscle constructs. In response to epigenetic drugs, myotube differentiation of C2C12 myoblast cells was promoted in two-dimensional cell cultures, but the levels of contractile force generation of tissue-engineered skeletal muscle constructs prepared by three-dimensional cell cultures were not correlated with the levels of myotube differentiation in two-dimensional cell cultures. In contrast, sarcomere formation and contractile activity in two-dimensional cell cultures were highly correlated with contractile force generation of tissue-engineered skeletal muscle constructs. Among the epigenetic drugs tested, trichostatin A significantly improved contractile force generation of tissue-engineered skeletal muscle constructs. Follistatin expression was also enhanced by trichostatin A treatment, suggesting the importance of follistatin in sarcomere formation of muscular tissues. These observations indicate that contractility data are indispensable for in vitro drug screening.

Original languageEnglish
Article number44570
JournalScientific reports
Volume7
DOIs
Publication statusPublished - Mar 16 2017

All Science Journal Classification (ASJC) codes

  • General

Fingerprint Dive into the research topics of 'In vitro drug testing based on contractile activity of C2C12 cells in an epigenetic drug model'. Together they form a unique fingerprint.

  • Cite this